ESMO 2022 | The future role of immunotherapy in head and neck cancers

Denis Soulieres, The Université de Montréal, Montréal, Canada, comments on upcoming developments in the use of immunotherapies in head and neck squamous cell carcinoma. The Phase III KEYNOTE-040 (NCT02252042) and KEYNOTE-048 (NCT02358031) trials have demonstrated the potential of incorporating immunotherapies, into combination therapies, with the latter trial showing robust 5-year survival rates. However, additional research is required to further enhance outcomes in a larger number of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.